Welcome to our dedicated page for Alpha Cognition news (Ticker: ACOGF), a resource for investors and traders seeking the latest updates and insights on Alpha Cognition stock.
Alpha Cognition Inc. (ACOGF) delivers cutting-edge AI solutions through cognitive computing platforms designed for enterprise data challenges. This dedicated news hub provides investors and professionals with verified updates directly from corporate communications and trusted financial sources.
Access chronological press releases covering product milestones, financial disclosures, and strategic initiatives. Key updates include earnings announcements, technology partnerships, research breakthroughs, and leadership developments within the cognitive AI sector.
All content undergoes strict verification to ensure alignment with regulatory standards and factual accuracy. The centralized format enables efficient tracking of Alpha Cognition's progress in advancing neural network applications and industry-specific AI tools.
Bookmark this page for streamlined monitoring of ACOGF's evolving market position and technological innovations. Combine these official updates with Stock Titan's analytical tools for comprehensive investment research.
Alpha Cognition Inc. (TSX-V:ACOG, OTCQB:ACOGF), a biopharmaceutical company focused on neurodegenerative disorders, will present at the Planet MicroCap Showcase: VEGAS 2023 on April 26, 2023, at 10:30 AM PST. CEO Michael McFadden will lead the presentation and answer questions afterward. Interested investors can attend live via webcast or schedule one-on-one meetings at the conference in Las Vegas. Alpha Cognition is developing ALPHA-1062, a new treatment aimed at Alzheimer's disease, designed to minimize gastrointestinal side effects. Further details can be found on the Planet MicroCap website.
Alpha Cognition Inc. (TSX-V: ACOG, OTCQB: ACOGF) has completed a second tranche of its private placement, issuing 6,952,427 units at $0.255 per unit, yielding gross proceeds of $1,772,869. This follows a first tranche, bringing total proceeds to $6,055,650 from 23,747,648 units. The funds will support clinical development programs, including a New Drug Application for ALPHA-1062, a new treatment for Alzheimer's disease. Securities are subject to a four-month hold period in Canada and a 12-month resale restriction in the U.S.
Alpha Cognition Inc. (TSX-V: ACOG, OTCQB: ACOGF) reported its financial results for Q4 and the full year ending December 31, 2022. The company is focused on submitting a New Drug Application (NDA) for ALPHA-1062, aimed at treating mild to moderate Alzheimer's disease, targeting a filing date in June/July 2023. Notably, R&D expenses increased to $8.8 million for 2022, driven by advancements in clinical studies. The company reported a net loss of $12.1 million for the year, with cash reserves of $2.1 million as of December 31, 2022. There is an ongoing effort to manage finances prudently and explore partnerships.
